James C. Chen

James C. Chen

Auto-generated profile, based on publicly available information

James C. Chen

Industrial Engineering Dept., National Tsing Hua University, Hsinchu, Taiwan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CHClaire A. Higgins
Claire A. Higgins
JCJames C. Chen
James C. Chen
JCJane E. Cerise
Jane E. Cerise
CJColin A. B. Jahoda
Colin A. B. Jahoda
ACAngela M. Christiano
Angela M. Christiano
Significance: Growth of de novo hair follicles in adult skin occurs by a process known as hair neogenesis. One way of initiating neogenesis is to place dermal papillae isolated from the hair follicle in contact with an overlying epidermis where they reprogram the epidermis to adopt a follicular fate. This approach, however, has not been successful using cultured human dermal papilla cells in human skin because the cells lose their ability to induce hair growth after expansion in vitro. In this paper, we demonstrate that by manipulating cell culture conditions to establish three-dimensional papilla spheroids, we restore dermal papilla inductivity. We also use several systems biology approaches to gain a comprehensive understanding of the molecular mechanisms that underlie this regenerative process.

22 September 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
MCMilène Kennedy Crispin
Milène Kennedy Crispin
JKJustin M. Ko
Justin M. Ko
BCBrittany G. Craiglow
Brittany G. Craiglow
SLShufeng Li
Shufeng Li
GSGautam Shankar
Gautam Shankar
BKBrett A. King
Brett A. King
BACKGROUND. Alopecia areata (AA) is an autoimmune disease characterized by hair loss mediated by CD8 + T cells. There are no reliably effective therapies for AA. Based on recent developments in the understanding of the pathomechanism of AA, JAK inhibitors appear to be a therapeutic option; however, their efficacy for the treatment of AA has not been systematically examined. METHODS. This was a 2-center, open-label, single-arm trial using the pan-JAK inhibitor, tofacitinib citrate, for AA with >50% scalp hair loss, alopecia totalis (AT), and alopecia universalis (AU). Tofacitinib (5 mg) was given twice daily for 3 months. Endpoints included regrowth of scalp hair, as assessed by the severity of alopecia tool (SALT), duration of hair growth after completion of therapy, and disease transcriptome. RESULTS. Of 66 subjects treated, 32% experienced 50% or greater improvement in SALT score. AA and ophiasis subtypes were more responsive than AT and AU subtypes. Shorter duration of disease and histological peribulbar inflammation on pretreatment scalp biopsies were associated with improvement in SALT score. Drug cessation resulted in disease relapse in 8.5 weeks. Adverse events were limited to grade I and II infections. An AA responsiveness to JAK/STAT inhibitors score was developed to segregate responders and nonresponders, and the previously developed AA disease activity index score tracked response to treatment. CONCLUSIONS. At the dose and duration studied, tofacitinib is a safe and effective treatment for severe AA, though it does not result in a durable response. Transcriptome changes reveal unexpected molecular complexity within the disease. TRIAL REGISTRATION. ClinicalTrials.gov NCT02197455 and NCT02312882. FUNDING. This work was supported by the US Department of Veterans Affairs Office of Research and Development, National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health grant R01 AR47223 and U01 AR67173, the National Psoriasis Foundation, the Swedish Society of Medicine, the Fernström Foundation, the Locks of Love Foundation, the National Alopecia Areata Foundation, and the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research.

2 October 2015 in Science Advances
Verified
Journal Article
Open access
PDF file
SHSivan Harel
Sivan Harel
CHClaire A. Higgins
Claire A. Higgins
JCJane E. Cerise
Jane E. Cerise
ZDZhenpeng Dai
Zhenpeng Dai
JCJames C. Chen
James C. Chen
ACAngela M. Christiano
Angela M. Christiano
Topical treatment of mouse and human skin with small-molecule inhibitors of the JAK-STAT pathway results in hair growth.

1 October 2014 in Cell
Verified
Journal Article
Closed access
JCJames C. Chen
James C. Chen
MAMariano J. Alvarez
Mariano J. Alvarez
FTFlaminia Talos
Flaminia Talos
HDHarshil Dhruv
Harshil Dhruv
GRGabrielle E. Rieckhof
Gabrielle E. Rieckhof
ACAndrea Califano
Andrea Califano

1 July 2018 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AJA. Jabbari
A. Jabbari
FSF. Sansaricq
F. Sansaricq
JCJ. Cerise
J. Cerise
JCJ.C. Chen
J.C. Chen
ABA. Bitterman
A. Bitterman
JMJ. Mackay-Wiggan
J. Mackay-Wiggan

1 May 2016 in EBioMedicine
Verified
Journal Article
Open access
AJAli Jabbari
Ali Jabbari
JCJane E. Cerise
Jane E. Cerise
JCJames C. Chen
James C. Chen
JMJulian Mackay-Wiggan
Julian Mackay-Wiggan
MDMadeleine Duvic
Madeleine Duvic
ACAngela M. Christiano
Angela M. Christiano
Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. In this study, we conducted whole genome gene expression analysis of 96 human scalp skin biopsy specimens from AA or normal control subjects. Based on gene expression profiling, samples formed distinct clusters based on the presence or absence of disease as well as disease phenotype (patchy disease compared with alopecia totalis or universalis). Differential gene expression analysis allowed us to robustly demonstrate graded immune activity in samples of increasing phenotypic severity and generate a quantitative gene expression scoring system that classified samples based on interferon and cytotoxic T lymphocyte immune signatures critical for disease pathogenesis.